_2020091018165303jzv.jpg "Decoding The World Of ETF")
My Account
My Account
Lupin share price added 3 percent in early trade on December 22 after the company received USFDA approval.
The company said that it has received approval for its Rufinamide Oral Suspension, 40 mg/ml, from the United States Food and Drug Administration (USFDA), to market a generic equivalent of Banzel Oral Suspension, 40 mg/ml, of Eisai Inc.
Rufinamide Oral Suspension is indicated for adjunctive treatment of seizures associated with Lennox-Gastaut syndrome (LGS) in pediatric patients 1 year of age and older, and in adults.
Rufinamide had estimated annual sales of USD 124.5 million in the US (IQVIA MAT September 2020).
At 09:26 hrs, Lupin was quoting at Rs 945.50, up Rs 13.80, or 1.48 percent on the BSE.
The share touched its 52-week high of Rs 1,121.85 and its 52-week low of Rs 505.00 on 18 September 2020 and 13 March 2020, respectively.
Currently, it is trading 15.72 percent below its 52-week high and 87.23 percent above its 52-week low.
The Indian companies that made the most from Atmanirbhar Bharat Watch more 
Business Insight | CII bats for bad banks in pre-budget talks: A look at the workings of a bad bank Watch more 
3 Point Analysis | Which Were The Best Performing Asset Classes In 2020? Watch more 
Ideas For Profit | Antony Waste IPO: Niche player in a growing market; should you subscribe? Watch more 
